Cargando…
Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study
BACKGROUND: Direct acting antivirals for hepatitis C virus have shown dramatic results in clinical trials. However, their effectiveness has yet to be demonstrated within observational cohorts which lack exclusion criteria found in randomized control trials. AIM: To determine the effectiveness of das...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501432/ https://www.ncbi.nlm.nih.gov/pubmed/28686590 http://dx.doi.org/10.1371/journal.pone.0176858 |
_version_ | 1783248781407420416 |
---|---|
author | Leventer-Roberts, Maya Hammerman, Ariel Brufman, Ilan Hoshen, Moshe Braun, Marius Ashur, Yaffa Lieberman, Nicky Balicer, Ran |
author_facet | Leventer-Roberts, Maya Hammerman, Ariel Brufman, Ilan Hoshen, Moshe Braun, Marius Ashur, Yaffa Lieberman, Nicky Balicer, Ran |
author_sort | Leventer-Roberts, Maya |
collection | PubMed |
description | BACKGROUND: Direct acting antivirals for hepatitis C virus have shown dramatic results in clinical trials. However, their effectiveness has yet to be demonstrated within observational cohorts which lack exclusion criteria found in randomized control trials. AIM: To determine the effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir in achieving sustained virological response. METHODS: Retrospective observational cohort study of all Clalit Health Services members with hepatitis C virus genotype 1 who were dispensed dasabuvir/ombitasvir/paritaprevir/ritonavir from January 1, 2015 to-November 31, 2015. RESULTS: There were 564 participants during the study period. The average age was 61.9 years, 52.0% were male, and 61.5% were born Eastern/Central Europe or Central Asia. The prevalence of diabetes was 31.7% and 70.3% were overweight/obese. Cirrhosis was present in 41.0% of participants, of whom 52.8% had stage 4 fibrosis. Of the cohort, 416 (74.8%) had follow-up viral load testing at 10 or more weeks after the end of treatment. We report a sustained virological response of 98.8% among those tested. CONCLUSIONS: Treatment with dasabuvir/ombitasvir/paritaprevir/ritonavir demonstrated a near universal effectiveness in achieving a sustained virological response among HCV patients in a large cohort. |
format | Online Article Text |
id | pubmed-5501432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-55014322017-07-25 Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study Leventer-Roberts, Maya Hammerman, Ariel Brufman, Ilan Hoshen, Moshe Braun, Marius Ashur, Yaffa Lieberman, Nicky Balicer, Ran PLoS One Research Article BACKGROUND: Direct acting antivirals for hepatitis C virus have shown dramatic results in clinical trials. However, their effectiveness has yet to be demonstrated within observational cohorts which lack exclusion criteria found in randomized control trials. AIM: To determine the effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir in achieving sustained virological response. METHODS: Retrospective observational cohort study of all Clalit Health Services members with hepatitis C virus genotype 1 who were dispensed dasabuvir/ombitasvir/paritaprevir/ritonavir from January 1, 2015 to-November 31, 2015. RESULTS: There were 564 participants during the study period. The average age was 61.9 years, 52.0% were male, and 61.5% were born Eastern/Central Europe or Central Asia. The prevalence of diabetes was 31.7% and 70.3% were overweight/obese. Cirrhosis was present in 41.0% of participants, of whom 52.8% had stage 4 fibrosis. Of the cohort, 416 (74.8%) had follow-up viral load testing at 10 or more weeks after the end of treatment. We report a sustained virological response of 98.8% among those tested. CONCLUSIONS: Treatment with dasabuvir/ombitasvir/paritaprevir/ritonavir demonstrated a near universal effectiveness in achieving a sustained virological response among HCV patients in a large cohort. Public Library of Science 2017-07-07 /pmc/articles/PMC5501432/ /pubmed/28686590 http://dx.doi.org/10.1371/journal.pone.0176858 Text en © 2017 Leventer-Roberts et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Leventer-Roberts, Maya Hammerman, Ariel Brufman, Ilan Hoshen, Moshe Braun, Marius Ashur, Yaffa Lieberman, Nicky Balicer, Ran Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study |
title | Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study |
title_full | Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study |
title_fullStr | Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study |
title_full_unstemmed | Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study |
title_short | Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study |
title_sort | effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis c virus in clinical practice: a population-based observational study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501432/ https://www.ncbi.nlm.nih.gov/pubmed/28686590 http://dx.doi.org/10.1371/journal.pone.0176858 |
work_keys_str_mv | AT leventerrobertsmaya effectivenessofdasabuvirombitasvirparitaprevirritonavirforhepatitiscvirusinclinicalpracticeapopulationbasedobservationalstudy AT hammermanariel effectivenessofdasabuvirombitasvirparitaprevirritonavirforhepatitiscvirusinclinicalpracticeapopulationbasedobservationalstudy AT brufmanilan effectivenessofdasabuvirombitasvirparitaprevirritonavirforhepatitiscvirusinclinicalpracticeapopulationbasedobservationalstudy AT hoshenmoshe effectivenessofdasabuvirombitasvirparitaprevirritonavirforhepatitiscvirusinclinicalpracticeapopulationbasedobservationalstudy AT braunmarius effectivenessofdasabuvirombitasvirparitaprevirritonavirforhepatitiscvirusinclinicalpracticeapopulationbasedobservationalstudy AT ashuryaffa effectivenessofdasabuvirombitasvirparitaprevirritonavirforhepatitiscvirusinclinicalpracticeapopulationbasedobservationalstudy AT liebermannicky effectivenessofdasabuvirombitasvirparitaprevirritonavirforhepatitiscvirusinclinicalpracticeapopulationbasedobservationalstudy AT balicerran effectivenessofdasabuvirombitasvirparitaprevirritonavirforhepatitiscvirusinclinicalpracticeapopulationbasedobservationalstudy |